日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A

利用机器学习方法估算中国重度A型血友病患儿的FVIII药代动力学参数

Wang, Yuntian; Ai, Di; Wang, Shuo; Li, Zekun; Li, Gang; Zhu, Yunqi; Zhong, Yuqi; Zhang, Wensheng; Wu, Runhui; Chen, Zhenping; Tang, Yongqiang

Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX

对伴有抑制因子的HA和HB患者的PBMC进行单细胞测序,揭示了其对FVIII和FIX的不同免疫反应。

Li, Enhao; Li, Zekun; Wang, Jinzeng; Wu, Haoyang; Xue, Yilun; Lou, Can; Chen, Zhenping; Liu, Feng; Wu, Wenman; Ding, Qiulan; Wu, Runhui; Wang, Xuefeng; Dai, Jing

Association of TCRαβ(+) double-negative T cells with the response to glucocorticoids in pediatric patients with immune thrombocytopenia

TCRαβ(+)双阴性T细胞与儿童免疫性血小板减少症患者对糖皮质激素反应的关联

Chen, Hui; Xie, Xingjuan; Ma, Jingyao; Fu, Lingling; Wu, Runhui; Chen, Zhenping

Cloud-edge-device collaborative computing in smart agriculture: architectures, applications, and future perspectives

智慧农业中的云-边缘-设备协同计算:架构、应用和未来展望

Yu, Pengpeng; Teng, Fei; Zhu, Wenhui; Shen, Chaoping; Chen, Zhenping; Song, Jinxiu

Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from China

一项来自中国的多中心前瞻性研究表明,对于重度持续性/慢性免疫性血小板减少症,阶梯式反应指导治疗方案优于基于血小板生成素受体激动剂的二线治疗方案:

Fu, Lingling; Lin, Xi; Chen, Zhenping; Wang, Zhifa; Liu, Yan; Wang, Lijuan; Hu, Yu; Ma, Jingyao; Wang, Nan; Cheng, Xiaoling; Ma, Jie; Wu, Runhui

Rituximab-first versus eltrombopag monotherapy in pediatric persistent/chronic immune refractory thrombocytopenia after first-line therapy: a prospective multicenter cohort study

利妥昔单抗一线治疗与艾曲波帕单药治疗一线治疗后儿童持续性/慢性免疫难治性血小板减少症的疗效比较:一项前瞻性多中心队列研究

Ma, Jingyao; Wang, Zhifa; Ouyang, Juntao; Lin, Zheyan; Fu, Lingling; Chen, Zhenping; Liu, Yan; Wang, Lijuan; Lin, Xi; Cheng, Xiaoling; Hu, Yu; Dong, Shuyue; Meng, Jinxi; Ma, Jie; Wu, Runhui

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial

一项多中心随机临床试验表明,与低剂量相比,中等剂量免疫耐受诱导疗法具有起效更快、出血更少且不增加成本的优势。

Li, Zhengping; Li, Zekun; Cheng, Xiaoling; Zhang, Heng; Yang, Can; Xu, Qian; Chen, Zhenping; Zhen, Yingzi; Li, Gang; Liu, Guoqing; Yao, Wanru; Zhou, Min; Jin, Jiao; Huang, Jie; Fang, Yongjun; Xie, Liangzhi; Poon, Man-Chiu; Wu, Runhui

Multicenter, real-world observational study of AVA therapy following ELT/HET switching in Chinese children with persistent/chronic primary ITP

一项多中心、真实世界观察性研究,旨在评估在中国持续性/慢性原发性ITP患儿中,ELT/HET方案转换后AVA治疗的疗效。

Liu, Jingjing; Wang, Zhifa; Wang, Nan; Ma, Jingyao; Wang, Lijuan; Liu, Yan; Meng, Jinxi; Dong, Shuyue; Hu, Yu; Ouyang, Juntao; Chen, Zhenping; Cheng, Xiaoling; Wu, Runhui

Urinary metabolomics predicts early rituximab response in steroid-nonresponsive pediatric patients with primary immune thrombocytopenia

尿液代谢组学预测对类固醇无反应的原发性免疫性血小板减少症患儿对利妥昔单抗的早期反应

Yu, Yuncui; Chen, Zhenping; Wei, Jing; Xie, Xingjuan; Ouyang, Juntao; Lin, Zheyan; Ma, Jingyao; Guo, Peng; Wu, Runhui; Gui, Jingang

Significant PK variability of plasma-derived FIX concentrates in chinese children with Haemophilia B: A fixed single-dose study of factor IX-CTBB

中国B型血友病患儿血浆来源的FIX浓缩物药代动力学变异性显著:一项固定单剂量因子IX-CTBB研究

Liu, Guoqing; Ai, Di; Li, Gang; Zhen, Yingzi; Wu, Xinyi; Yao, Wanru; Wei, Yunyun; Li, Zekun; Zhou, Yaohan; Wu, Runhui; Chen, Zhenping